Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 5/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.45 |
| ▸ | PYGL | P06737 | 5/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1338655 | 1.00 | CYP11B1 (0.45) | CYP11B1CYP11B2PYGLHPGDNPC1 | |
| SCHEMBL1337293 | 0.86 | POLB (0.53) | CYP11B1CYP11B2POLBGLAMAPT | |
| SCHEMBL1337295 | 0.86 | POLB (0.53) | CYP11B1CYP11B2POLBGLAMAPT | |
| SCHEMBL9612022 | 0.84 | CYP1A2 (0.45) | CYP11B1CYP11B2HPGDNPC1LMNA | |
| SCHEMBL1339680 | 0.81 | CYP11B1 (0.56) | CYP11B1CYP11B2NPC1POLBGLA | |
| SCHEMBL1339678 | 0.81 | CYP11B1 (0.56) | CYP11B1CYP11B2NPC1POLBGLA | |
| SCHEMBL23842714 | 0.80 | CYP11B1 (0.47) | CYP11B1CYP11B2NPC1POLBGLA | |
| SCHEMBL30195828 | 0.80 | CYP11B1 (0.47) | CYP11B1CYP11B2NPC1POLBGLA | |
| SCHEMBL2703611 | 0.80 | CYP11B1 (0.53) | CYP11B1CYP11B2HPGDLMNAPOLB | |
| SCHEMBL14067060 | 0.80 | CYP11B1 (0.53) | CYP11B1CYP11B2HPGDLMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063061-B2 | 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites | SANOFI-AVENTIS (FR) | 2011-11-22 | — | — | US | disclosed |
| EP-1940840-B1 | 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2010-07-21 | — | — | EP | disclosed |
| US-20080262020-A1 | 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof | SANOFI-AVENTIS (FR) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262020-A1 | 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof | CYP11B2, CYP11B1, CYP2D6 | CYP11B1 2/4885CYP11B2 1/4885PYGL 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.